VIEKIRA PAK (COPACKAGED) Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Viekira Pak (copackaged) patents expire, and when can generic versions of Viekira Pak (copackaged) launch?
Viekira Pak (copackaged) is a drug marketed by Abbvie Inc and is included in one NDA. There are seventeen patents protecting this drug.
This drug has six hundred and sixteen patent family members in fifty-three countries.
The generic ingredient in VIEKIRA PAK (COPACKAGED) is dasabuvir sodium; ombitasvir, paritaprevir, ritonavir. One supplier is listed for this compound. Additional details are available on the dasabuvir sodium; ombitasvir, paritaprevir, ritonavir profile page.
DrugPatentWatch® Generic Entry Outlook for Viekira Pak (copackaged)
Viekira Pak (copackaged) was eligible for patent challenges on December 19, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 18, 2033. This may change due to patent challenges or generic licensing.
There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VIEKIRA PAK (COPACKAGED)
International Patents: | 616 |
US Patents: | 17 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Patent Applications: | 42 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VIEKIRA PAK (COPACKAGED) |
DailyMed Link: | VIEKIRA PAK (COPACKAGED) at DailyMed |
-patent-expirations.png)
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VIEKIRA PAK (COPACKAGED)
Generic Entry Date for VIEKIRA PAK (COPACKAGED)*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for VIEKIRA PAK (COPACKAGED)
US Patents and Regulatory Information for VIEKIRA PAK (COPACKAGED)
VIEKIRA PAK (COPACKAGED) is protected by seventeen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VIEKIRA PAK (COPACKAGED) is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VIEKIRA PAK (COPACKAGED)
Formulations of pyrimidinedione derivative compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Solid pharmaceutical dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Solid pharmaceutical dosage form
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION.
Macrocyclic hepatitis C serine protease inhibitors
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN.
Methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN
Solid compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Anti-viral compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING OMBITASVIR
Compositions and methods for treating HCV
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING PARITAPREVIR
Anti-infective agents and uses thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Formulations of pyrimidinedione derivative compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HCV INFECTION USING DASABUVIR
Expired US Patents for VIEKIRA PAK (COPACKAGED)
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | See Plans and Pricing | See Plans and Pricing |
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | See Plans and Pricing | See Plans and Pricing |
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | See Plans and Pricing | See Plans and Pricing |
Abbvie Inc | VIEKIRA PAK (COPACKAGED) | dasabuvir sodium; ombitasvir, paritaprevir, ritonavir | TABLET;ORAL | 206619-001 | Dec 19, 2014 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VIEKIRA PAK (COPACKAGED)
When does loss-of-exclusivity occur for VIEKIRA PAK (COPACKAGED)?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13330993
Estimated Expiration: See Plans and Pricing
Brazil
Patent: 2015008927
Estimated Expiration: See Plans and Pricing
Canada
Patent: 88883
Estimated Expiration: See Plans and Pricing
China
Patent: 4853752
Estimated Expiration: See Plans and Pricing
Patent: 9260207
Estimated Expiration: See Plans and Pricing
Eurasian Patent Organization
Patent: 8481
Estimated Expiration: See Plans and Pricing
Patent: 2913
Estimated Expiration: See Plans and Pricing
Patent: 1590752
Estimated Expiration: See Plans and Pricing
Patent: 1791354
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 08808
Estimated Expiration: See Plans and Pricing
Japan
Patent: 66635
Estimated Expiration: See Plans and Pricing
Patent: 15534985
Estimated Expiration: See Plans and Pricing
Patent: 18065858
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 15004973
Estimated Expiration: See Plans and Pricing
Singapore
Patent: 201503051Q
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VIEKIRA PAK (COPACKAGED) around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 201408665 | See Plans and Pricing | |
Poland | 2206500 | See Plans and Pricing | |
Australia | 2010258769 | Anti-viral compounds to treat HCV infection | See Plans and Pricing |
South Korea | 20140143152 | ANTI-VIRAL COMPOUNDS | See Plans and Pricing |
Israel | 122546 | COMBINATION OF RITONAVIR AND A DRUG METABOLIZED BY CYTOCHROME P450 MONOXYGENASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VIEKIRA PAK (COPACKAGED)
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2340029 | 304 50009-2015 | Slovakia | See Plans and Pricing | PRODUCT NAME: PARITAPREVIR; REGISTRATION NO/DATE: EU/1/14/982/001 20150119 |
2203431 | C02203431/01 | Switzerland | See Plans and Pricing | FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS |
2203431 | 38/2015 | Austria | See Plans and Pricing | PRODUCT NAME: DASABUVIR ODER EIN SALZ DAVON, EINSCHLIESSLICH DASABUVIR-NATRIUM-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
2340029 | PA2015011,C2340029 | Lithuania | See Plans and Pricing | PRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115 |
2692346 | CR 2017 00049 | Denmark | See Plans and Pricing | PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/17/1213 20170728 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |